407 related articles for article (PubMed ID: 25826089)
21. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
[TBL] [Abstract][Full Text] [Related]
22. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
Singh R; Peng S; Viswanath P; Sambandam V; Shen L; Rao X; Fang B; Wang J; Johnson FM
EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 31040125
[TBL] [Abstract][Full Text] [Related]
23. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
25. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
26. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
28. Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
Weiß LM; Hugle M; Romero S; Fulda S
Int J Cancer; 2016 Jan; 138(2):497-506. PubMed ID: 26260582
[TBL] [Abstract][Full Text] [Related]
29. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
[TBL] [Abstract][Full Text] [Related]
31. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
32. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
de Oliveira JC; Brassesco MS; Pezuk JA; Morales AG; Valera ET; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
J Drugs Dermatol; 2012 May; 11(5):587-92. PubMed ID: 22527426
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
[TBL] [Abstract][Full Text] [Related]
35. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
37. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
38. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
39. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
40. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
Lund-Andersen C; Patzke S; Nähse-Kumpf V; Syljuåsen RG
Radiother Oncol; 2014 Feb; 110(2):355-61. PubMed ID: 24502970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
